PEPG (PepGen) Issuance of Debt : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is PepGen Issuance of Debt?

PepGen's Issuance of Debt for the three months ended in Sep. 2024 was $0.00 Mil.

PepGen's Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

PepGen Issuance of Debt Historical Data

The historical data trend for PepGen's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PepGen Issuance of Debt Chart

PepGen Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Issuance of Debt

PepGen Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Issuance of Debt	Get a 7-Day Free Trial											-	-	-	-	-

PepGen Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

PepGen Issuance of Debt Related Terms

Thank you for viewing the detailed overview of PepGen's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

PepGen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PepGen Inc (NAS:PEPG) » Definitions » Issuance of Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Harrison Avenue, 8th Floor, Boston, MA, USA, 02118

Website

https://www.pepgen.com

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Executives

Michelle L Mellion	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Niels Svenstrup	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
James G Mcarthur	director, officer: President and CEO	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Jaya Goyal	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
James E Flynn	10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Oxford Science Enterprises Plc	10 percent owner	46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Laurie Keating	director	300 THIRD STREET, CAMBRIDGE MA 02142
Christopher Ashton	director	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Management Company, L.p. (series C)	10 percent owner, other: *Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Noel Donnelly	officer: Chief Financial Officer	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Sonia Bracegirdle	officer: See Remarks	PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Mgmt V, L.p.	10 percent owner, other: *Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Private Design Fund V, L.p.	10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017